Mainz Biomed (MYNZ) Competitors

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

In the previous week, Senti Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

25.7% of Senti Biosciences shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Senti Biosciences has a consensus price target of $8.50, suggesting a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Mainz Biomed.

Mainz Biomed has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Mainz Biomed's return on equity of 0.00% beat Senti Biosciences' return on equity.

Celularity has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

In the previous week, Celularity had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Celularity and 0 mentions for Mainz Biomed. Celularity's average media sentiment score of 0.20 beat Mainz Biomed's score of 0.00 indicating that Celularity is being referred to more favorably in the media.

19.0% of Celularity shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Celularity currently has a consensus price target of $6.00, indicating a potential upside of 529.66%. Given Celularity's stronger consensus rating and higher probable upside, analysts plainly believe Celularity is more favorable than Mainz Biomed.

Mainz Biomed has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Mainz Biomed has a net margin of 0.00% compared to Celularity's net margin of -198.75%.

Oncobiologics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

In the previous week, Oncobiologics had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 4 mentions for Oncobiologics and 0 mentions for Mainz Biomed. Oncobiologics' average media sentiment score of 1.00 beat Mainz Biomed's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

11.2% of Oncobiologics shares are owned by institutional investors. 2.8% of Oncobiologics shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oncobiologics currently has a consensus price target of $4.50, indicating a potential upside of 1,761.81%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than Mainz Biomed.

Mainz Biomed has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Dyadic International has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Dyadic International has higher revenue and earnings than Mainz Biomed. Dyadic International is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Mainz Biomed has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. Mainz Biomed's return on equity of 0.00% beat Dyadic International's return on equity.

In the previous week, Dyadic International had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for Mainz Biomed. Dyadic International's average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

28.0% of Dyadic International shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 289.56%. Given Dyadic International's stronger consensus rating and higher possible upside, equities analysts plainly believe Dyadic International is more favorable than Mainz Biomed.